American Society of Hematology

Figure 1

$Figure 1. Expression of Nanog in hematopoiteic cells. (A) Expression of Nanog in the indicated cell types was measured by quantitative reverse transcription polymerase chain reaction (QRT-PCR). (B) Expression of Oct3/4 and Sox2 in the indicated cell types was measured by QRT-PCR. The values were normalized using the Gapdh, βactin, and HPRT control genes. EB5 day 0, undifferentiated EB5 ES cell line19; EB5 day 5, EB5 ES cells that were cultured in the absence of LIF for 5 days; testis, unfractionated testis cells; BM GM, bone marrow cells expressing either Gr1 or Mac1; BM CD19, bone marrow cells expressing CD19; BM KSL, lineage negative bone marrow cells that express c-Kit and Sca-1; thymus DN, CD4−CD8− thymocytes; thymus DP, CD4+CD8+ thymocytes; thymus SP, pooled CD4 SP and CD8 SP thymocytes; thymus γδ, γδT cells. This analysis was performed 3 times with similar results obtained in 2 other independent experiments.$

Expression of Nanog in hematopoiteic cells. (A) Expression of Nanog in the indicated cell types was measured by quantitative reverse transcription polymerase chain reaction (QRT-PCR). (B) Expression of Oct3/4 and Sox2 in the indicated cell types was measured by QRT-PCR. The values were normalized using the Gapdh, βactin, and HPRT control genes. EB5 day 0, undifferentiated EB5 ES cell line¹⁹; EB5 day 5, EB5 ES cells that were cultured in the absence of LIF for 5 days; testis, unfractionated testis cells; BM GM, bone marrow cells expressing either Gr1 or Mac1; BM CD19, bone marrow cells expressing CD19; BM KSL, lineage negative bone marrow cells that express c-Kit and Sca-1; thymus DN, CD4⁻CD8⁻ thymocytes; thymus DP, CD4⁺CD8⁺ thymocytes; thymus SP, pooled CD4 SP and CD8 SP thymocytes; thymus γδ, γδT cells. This analysis was performed 3 times with similar results obtained in 2 other independent experiments.

This Feature Is Available To Subscribers Only